Abstract
Expression levels of the urokinase-type plasminogen activator receptor (uPAR) represent an established biomarker for poor prognosis in a variety of human cancers. The objective of the present study was to explore whether noninvasive PET can be used to perform a quantitative assessment of expression levels of uPAR across different human cancer xenograft models in mice and to illustrate the clinical potential of uPAR PET in future settings for individualized therapy.
Original language | English |
---|---|
Journal | Journal of Nuclear Medicine |
Volume | 53 |
Issue number | 1 |
Pages (from-to) | 138-45 |
Number of pages | 8 |
ISSN | 0161-5505 |
DOIs | |
Publication status | Published - 2012 |
Keywords
- Animals
- Cell Transformation, Neoplastic
- Colorectal Neoplasms
- Copper Radioisotopes
- Female
- Gene Expression Regulation, Neoplastic
- HT29 Cells
- Heterocyclic Compounds, 1-Ring
- Humans
- Mice
- Neoplasm Invasiveness
- Oligopeptides
- Positron-Emission Tomography
- Positron-Emission Tomography and Computed Tomography
- Radiochemistry
- Receptors, Urokinase Plasminogen Activator